Sudden death is the first feature of coronary artery disease in almost a quarter of those who die from it. Up to 50000 seemingly healthy British people die each year of the disease together with a similar number with known angina. These deaths occur outside hospital when medical aid is not available, and they can be prevented only by measures such as those taken in Seattle, where most of the adult population are trained in resuscitation procedures and fire brigade crews reach the victims within minutes.' Death is caused by ventricular fibrillation, which is usually due to potentially reversible myocardial ischaemia, rather than myocardial infarction. The risk of sudden cardiac death depends on the severity of the underlying arterial and myocardial disorder,2 but identification ofpeople at risk ofsudden death is necessarily confined to those who have already shown some hint of trouble.
Not only is myocardial ischaemia frequently painless but there is little correlation between the severity of the symptoms and the degree of risk, although when sudden death does occur severe multivessel coronary disease is the usual finding.3 Coronary artery bypass surgery improves survival in high risk patients, particularly those who have critical narrowing of the left main coronary artery4 5 or triple vessel disease. [5] [6] [7] Up to 10% of patients after infarction have left main stem disease, and no less than 3000 have "three vessel" disease. 8 Bertrand et al found that 5400 of patients with acute anterior infarcts and 25% with inferior infarcts had subtotal obstruction of the left anterior descending coronary artery.9 In a study of patients with subendocardial infarcts (a group known to be at risk ofearly recurrent infarction) 3000 had subtotal obstruction of the left anterior descending artery either alone or in association with stenosis of a second coronary artery. 10 Transluminal balloon angioplasty is an alternative form of treatment with a growing application" but, like surgical bypass, it must be preceded by coronary angiography.
Each year about a quarter of a million patients in Britain have a myocardial infarction, and nearly half die from italmost a third from ventricular fibrillation before admission to hospital, 10% from cardiac failure in the coronary care unit, and about 10% from various causes later in the ensuing year. Pantridge Of the various drugs that have been given after myocardial infarction-agents which influence platelet behaviour,20 antiarrhythmic drugs,21 and beta adrenergic blockers22-25-only beta blockers have been convincingly shown to reduce mortality. The delay in documenting the effect of beta blockers is explained by the exclusion of many high risk patients from the drug trials, which increased the proportion of patients at low risk in whom therapeutic intervention would be unlikely to prolong survival.'3 Beta blockers are not effective antiarrhythmic agents, but (like sympathectomy) they prevent ventricular fibrillation after acute coronary occlusion in animals25 and so probably they exert their beneficial effects by reducing ischaemia and hence ventricular fibrillation, which is provoked by ischaemia. The patients most likely to benefit from them are those with continuing ischaemia.
A strategy for managing patients after myocardial infarction has emerged.26 The patient who will do well may be recognised by his good exercise tolerance, good left ventricular function, and absence of ventricular arrhythmia. There is no evidence to suggest that treatment with beta adrenergic blockers will be of benefit.'3 Patients with recurrent angina or evidence of inducible ischaemia should undergo prompt coronary angiography and those with left main stem 
